Notice Board Topics

Summer School, June 2009 Photos from the London Pain Consortium Summer School, held 21st-26th June 2009 in El Escorial, Madrid, Spain.

There are currently no summer schools scheduled. Please continue to check the website for updates.
Europain consortium receives EU and industry funding and begins five year research into better treatments for chronic pain Europain, a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a five-year research project to understand and improve treatment of chronic pain. The project will receive 6M€ from the IMI as well as 12.5M€ in kind contribution from the European Federation of Pharmaceutical Industries and Associations (EFPIA) over the coming five years.

One in five adults suffers from chronic pain. This constitutes a major cause of long-term sick leave and forced early retirement, placing a great financial burden on both individuals and healthcare systems. Despite extensive research programmes by biopharmaceutical companies and academia, there remains a need for treatments that are more effective and with fewer side-effects.

Europain has established an international team of leading researchers and clinicians from both academia and industry to undertake multidisciplinary translational research. This team aims to increase the understanding of chronic pain mechanisms, help to develop novel analgesics, and develop better biomarkers for pain. Their ultimate goal is to improve the lives of people suffering from chronic pain.

During the five-year project, Europain will undertake a large number of preclinical and clinical studies. The program will be delivered through collaboration between laboratories in the Europain network, sharing resources to improve the value derived from the budget. Results will be made public during and after the project, ensuring that the knowledge created can be widely applied to the development of better therapies for patients suffering from chronic pain.

King’s College London, the managing entity of Europain and the academic lead institution will contribute to both the pre-clinical and clinical aspects of the project. One role will be to study the expression of potential pain mediators in both animal models of pain and samples from patients suffering from chronic pain. The role of novel pain mediators will then be investigated using an array of techniques ranging from cell culture to quantitative sensory testing in humans.

Professor Steve McMahon, who along with Dr Dave Bennett will be running the project at King’s, comments: ‘There are some big questions facing the pain field at the moment and this consortium, drawing on the skills and expertise of both academia and industry, is in a unique position to address them’.

The consortium network involves scientists representing 12 renowned European Universities: King’s College London (Academic lead), University College London, Imperial College London, the University of Oxford, the Christian-Albrechts-University of Kiel, the Medical Faculty Mannheim/Heidelberg University, the Technische Universität München, the Goethe University of Frankfurt, the BG University Hospital Bergmannsheil/Ruhr University Bochum, the University Hospitals of Aarhus, Rigshospitalet Copenhagen, University of Southern Denmark, the SME Neuroscience Technologies from Barcelona, and the research resources and expertise of Europe’s most active pharmaceutical companies working in the field of analgesics, including AstraZeneca (co-ordinator), Boehringer-Ingelheim, Eli Lilly, Esteve, Pfizer, Sanofi-Aventis, UCB Pharma.

About the Innovative Medicines Initiative

IMI is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
www.imi.europa.eu.
Seminar Series There are currently no seminars scheduled.…
 
Welcome To London Pain Consortium
Chronic pain affects the lives of many people. These pains can last for months or years and reduce the sufferers quality of life and can lead to secondary symptoms such as anxiety and depression. Our ability to treat these chronic pain states is currently limited.

The London Pain Consortium was formed in June 2002 by a grant from the Wellcome Trust, under its Integrative Animal and Human Physiology Initiative (IAHP). The purpose of the consortium is to undertake internationally competitive research in pain research and to train scientists in the integrative physiology and genomics of pain.

Our research focuses on the genomics of pain at several levels, including transcriptional profiling and the establishment of a pain database, the study of transgenic mice and the evaluation of pain sensitivity in people (more details).

In 2008 the London Pain Consortium was re-funded for a further 5 years under the Wellcome Trust Strategic Awards (more details).

Our training programme includes a 4 year PhD scheme, multidisciplinary post-doctoral fellowships, Ph.D. training for clinicians and opportunities for summer students (more details).




Research Activities

The Consortium (Strategic Award) currently funded research projects:
1. The neural substrates of the association between neuropathic pain and negative affect. more details
2. Higher level processing of sensory messages in different pain states. more details
3. Protein expression profiling of laser microdissected-dorsal horn laminae of chronic pain model rats. more details
4. Pan-DRG neuronal gene ablation for mechanistic studies into neuropathic pain. more details
5. Experimental pain models in humans and heritability of pain traits. more details
6. Bioinformatics protocols exploiting text mining and function prediction algorithms to reveal pain mediating gene candidates. more details
7. Functional imaging in persistent pain models and chronic pain patients. more details
8. In vivo gene knock-down and knock-out in spinal cord and DRG. more details

Previous projects funded by the Consortium (IAHP)
1. Tissue-specific and inducible knock-outs. more details
2. Functional properties of identified trigeminal primary afferents and adaptive changes following acute and chronic inflammation. more details
3. Mechanisms of HIV viral envelope protien gp120-induced painful neuropathy. more details
4. Rodent model of Zoster-associated pain. more details
5. Characterisation of mouse dorsal horn organisation. more details
6. Cannabinoid signalling in the pain pathway. more details
7. The Mechanisms of secondary hyperalgesia. more details
8. The Functional Development of Supraspinal Pain Processing in the Human Neonate and Infant. more details
9. Data Mining to reveal potentially novel genes and biological processes involved in the pain response. more details
10. The role of genetics and environment in pain. more details
11. NK-1 Receptors and developing pain pathways. more details
12. Using RNA interference to study the role of potassium channels in neuropathic pain. more details